Alexion’s rare disease drug Soliris has been approved in a new use in Europe, to tackle a disorder of the optic nerves for which it recently got FDA approval.
Some good news for the UK industry in turbulent times is always welcome, and several announcement this month showed us why the biotech sector in the country is looking extremely promising g
